Crospon Receives 510(k) FDA Clearance for Endoflip® with Flip® Topography Module

This Week’s News in Review

This Week's News in Review! Medical Device News Magazine keeps our readers up-to-date on breaking industry news! Learn how Medical Device News Magazine can help...

New Research Shows Nearly Half of Elderly Suffer Decreased Mobility During Lockdown

In a survey of UK adults with parents over the age of 75, while over half (52%) of respondents remain worried about their parents catching Covid, 48 percent are concerned about parental loneliness, and 46 percent about their parents falling alone and not being able to get up or get help. This figure remained high even among those whose parents are in care homes, with 37% of respondents still most concerned about parents falling over.

American College of Cardiology Names Ravee Kurian COO/CFO

Kurian comes to ACC following a 20-year stint at Publicis Sapient, a leading technology and communications consultancy, where he led critical and sensitive digital transformation initiatives for Fortune 500 and U.S. federal clients.

Endoflip 2.0 with cart webready
Company reports that the new Endoflip® System Will Greatly Improve the Quality of Patient Experience During Swallow Testing

Crospon, an endoscopic diagnostics company, today announced it has received US Food and Drug Administration (FDA) 510(k) clearance for its Endoflip® System with Flip® Topography Module, providing a new way for clinicians to assess patient motility disorders during endoscopy.

Continuing Crospon’s commitment to deliver information into the hands of gastroenterologists, the next generation of the Endoflip® System, Endoflip® 2.0, introduces imaging software that displays real-time esophageal contractility patterns on a 24” touch-screen. The unique repetitive visual cues of the patented Endoflip® technology enables gastroenterologists, for the first time, to investigate for conditions such as achalasia, GEJ outflow obstruction and other major or minor disorders of peristalsis during endoscopy. EndoFLIP 2.0 also introduces the new capability to capture and store Endoflip® images in electronic patient records.

John O’Dea, CEO and Founder of Crospon highlights, “This clearance represents a significant milestone for our organisation as we can now offer physicians an additional tool that can be used during endoscopy, along with other diagnostic methods, to evaluate patients with symptoms consistent with gastrointestinal motility disorders.”

O’Dea concluded, “The stand out benefit of this application, for both patients and caregivers, is that the Flip® Topography assessment can be performed in less than five minutes during upper endoscopy on a sedated patient. In addition to significantly reducing discomfort, the patient may not have to wait for testing at a specialised center, thereby reducing their time to treatment. While not always a substitute for manometry, Endoflip® 2.0 can reveal situations of non-obstructive dysphagia which may benefit from further evaluation from manometry.”

The company notes that shipments of Endoflip® 2.0 systems will commence in June 2017.

spot_img

DON'T MISS

Dr Jonathan Slotkin Appointed to Peer Well Board of Directors

Alongside the appointment, PeerWell is launching its new clinical practice, PeerWell Health.

Zimmer Biomet Announces New Appointments to Executive Leadership Team

Wilfred van Zuilen Appointed as President of Europe, Middle East and Africa. Nitin Goyal, M.D. Appointed to Newly Created Role of Chief Science, Technology and Innovation Officer.

Subscribe to Medical Device News Magazine here.

Related Articles